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Abstract
Objective
To discover common genetic variants associated with poststroke outcomes using a genome-
wide association (GWA) study.
Methods
The study comprised 6,165 patients with ischemic stroke from 12 studies in Europe, the United
States, and Australia included in the GISCOME (Genetics of Ischaemic Stroke Functional
Outcome) network. The primary outcome was modified Rankin Scale score after 60 to 190
days, evaluated as 2 dichotomous variables (0–2 vs 3–6 and 0–1 vs 2–6) and subsequently as an
ordinal variable. GWA analyses were performed in each study independently and results were
meta-analyzed. Analyses were adjusted for age, sex, stroke severity (baseline NIH Stroke Scale
score), and ancestry. The significance level was p < 5 × 10−8.
Results
We identified one genetic variant associated with functional outcome with genome-wide sig-
nificance (modified Rankin Scale scores 0–2 vs 3–6, p = 5.3 × 10−9). This intronic variant
(rs1842681) in the LOC105372028 gene is a previously reported trans-expression quantitative
trait locus for PPP1R21, which encodes a regulatory subunit of protein phosphatase 1. This
ubiquitous phosphatase is implicated in brain functions such as brain plasticity. Several variants
detected in this study demonstrated suggestive association with outcome (p < 10−5), some of
which are within or near genes with experimental evidence of influence on ischemic stroke
volume and/or brain recovery (e.g., NTN4, TEK, and PTCH1).
Conclusions
In this large GWA study on functional outcome after ischemic stroke, we report one significant
variant and several variants with suggestive association to outcome 3 months after stroke onset
with plausible mechanistic links to poststroke recovery. Future replication studies and explo-
ration of potential functional mechanisms for identified genetic variants are warranted.
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Functional outcomes after ischemic stroke have a wide range
of interindividual variability, from complete recovery to per-
sistent severe disability.1 Although a large number of factors
influence recovery after ischemic stroke, such as age and initial
stroke severity, a discernible portion of this interindividual
variation remains unexplained by clinical factors.1 The un-
explored mechanisms behind this variation represent poten-
tial keys in the search for a personalized poststroke
management approach that would include accurate prog-
nostic prediction as well as patient-tailored treatment, sec-
ondary prevention, and rehabilitation.
Genetic factors may account for part of the variability in stroke
outcomes. Studies in humans and animals support a genetic
influence on recovery after brain injury.2–4 In addition, genetic
variants identified through candidate gene studies have been
reported to associate with functional outcome after stroke,
e.g., within the brain-derived neurotrophic factor and
cyclooxygenase-2 genes,5–7 although these candidate gene
study results have been inconsistent and need replication.1 To
date, no genome-wide association (GWA) study has been
published on functional outcome after overall ischemic stroke.
Such a hypothesis-free approach may identify variants in-
dicating novel pathways for poststroke pathophysiologic
processes or recovery, and thereby suggest new targets for
interventions and drug development.
The Genetics of Ischaemic Stroke Functional Outcome
(GISCOME) network aims to identify genetic variants that
may influence functional outcome after ischemic stroke.8
Here, we present the results from a GWA study of functional
outcome as assessed by the modified Rankin Scale (mRS) at 3
months after ischemic stroke.
Methods
Study population
The GISCOME study population and analysis plan have been
previously described in detail.8 In brief, the GISCOME study
Glossary
EC = endothelial cell; eQTL = expression quantitative trait locus; GISCOME = Genetics of Ischaemic Stroke Functional
Outcome; GTEx = Genotype-Tissue Expression; GWA = genome-wide association; HGVD = Human Genetic Variation
Database; mRS = modified Rankin Scale; NIHSS = NIH Stroke Scale; OR = odds ratio; PP1 = protein phosphatase 1; SNP =
single-nucleotide polymorphism.
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population consists of patients with ischemic stroke of mainly
European ancestry aged 18 years and older from 12 study
locations in Europe, the United States, and Australia. After the
publication of the GISCOME study protocol,8 2 additional
sets of data from (1) the Sahlgrenska Academy Study on
Ischemic Stroke, and (2) the Malmo¨ Diet and Cancer Study
have been added (data available from Dryad, supplemental
Methods and tables e-1 and e-2, doi.org/10.5061/dryad.
s38kf65). The GISCOME study includes centers with mRS
and genotype data contributing to the International Stroke
Genetics Consortium and the National Institute of Neuro-
logical Disorders and Stroke – StrokeGeneticsNetwork (SiGN)
study efforts studying genetics of stroke risk. We did not have
any additional cohorts available at the time of this study for
replication.
Standard protocol approvals, registrations,
and patient consents
All participants provided written informed consent to par-
ticipate. For participants who were unable to communicate,
consent was obtained from their next of kin. Local ethics
committees approved the individual studies.
Outcome
The mRS as close as possible to 90 days (60–190 days permit-
ted) was selected to assess functional outcome, as described in
the analysis plan.8 The majority of the included studies (≈80%)
assessed mRS at 3 months ± 2 weeks.8 In most studies, this was
done by face-to-face interviews. In 3 studies (Lund Stroke
Register, Malmo¨ Diet and Cancer Study, and parts of the Sahl-
grenska Academy Study on Ischemic Stroke), data from the
Swedish quality register for stroke (Riksstroke) were used to
assessmRS by a validated translation algorithm.8,9 This approach
prevented a differentiation between the mRS scores 0, 1, and 2.
Based on our a priori analysis plan, we analyzed mRS as 2
dichotomous variables, (1) mRS 0–2 vs 3–6 and (2) mRS 0–1
vs 2–6, and also as the full ordinal scale variable. ThemRS 0–2
vs 3–6 and ordinal scale analyses included a larger number of
participants. Analyses of mRS 0–1 vs 2–6 were performed to
explore whether a second dichotomization could identify any
strong associations that were not picked up by the other
analyses. In addition, we made an explorative effort to in-
vestigate potential associations with infarcts in subcortical and
cortical locations separately. Since information about infarct
location was not available, we divided the cases into small
vessel disease (referred to as lacunar stroke) and other sub-
types (referred to as nonlacunar stroke), according to subtype
classifications in TOAST (Trial of ORG 10172 in Acute
Stroke Treatment).10 A total of 992 patients had lacunar
stroke, 3,991 patients had nonlacunar stroke, and for 1,182
individuals, this information was missing.
GWA analysis and meta-analysis
The methods for genotyping, imputation, and quality control
of genotype data are described in data available from Dryad
(supplemental Methods and tables e-1 and e-2, doi.org/10.
5061/dryad.s38kf65). Multivariable models were used for
analyses of each outcome variable, under an additive genetic
model. We aimed to explore genetic variants associated with
functional outcome that were independent of stroke severity.
In this primary model, results were adjusted for age, sex, an-
cestry (up to the first 5 principal components [data available
from Dryad, table e-3]), and baseline stroke severity as
assessed by the NIH Stroke Scale (NIHSS) at 0 to 10 days
post stroke onset, with preference to as close to day 0–1 as
possible.8 In addition, models without adjustment for baseline
stroke severity were performed for each outcome for com-
parison; however, unless otherwise stated, all results in this
report refer to the primary model as described above.
All dichotomized analyses were performed with logistic re-
gression using PLINK software version 1.90b4.6.11 The full
mRS was analyzed with ordinal logistic regression under
a cumulative logit model using theMATLABmnrfit algorithm
(MATLAB Statistics and Machine Learning Toolbox Release
2016b; The MathWorks, Inc., Natick, MA). Under the pro-
portional odds assumption, the effect of a predictor single-
nucleotide polymorphism (SNP) is invariant of the choice of
outcome categories. As a result, estimates from all study
cohorts, including those that did not separate mRS 0–2, are
comparable in ordinal regression. Furthermore, one unit
change in the dosage of a variant with regression coefficient β
suggests a change in the odds of an mRS score lower than or
equal to x vs higher than x by a factor OR = e−β, equally for
all scores x. We tested deviations from proportional odds for
all reported variants from the ordinal models. No significant
deviations were found.
Inverse variance-weighted fixed-effects meta-analysis was
performed using METAL software.12 Variants with minor
allele frequency <0.01 were excluded. Variants that were
missing in >50% of cohorts were also excluded. After filtering,
approximately 8.5 million SNPs were included in each of the
final meta-analyses. Quantile-quantile plots are shown in
figures 1 and 2 and in data available fromDryad (figures e-1 to
e-4, doi.org/10.5061/dryad.s38kf65), and genomic inflation
factors (λ) are displayed in data available from Dryad (table
e-4). There was no sign of population stratification based on
these measures. Heterogeneity of SNP effects between studies
was tested in the meta-analysis.
Markers with p values <5 × 10−8 were considered significant
for association with outcome, while markers with p values
<1 × 10−5 were considered suggestive. To facilitate compar-
ison of the results from the dichotomized and ordinal analy-
ses, we present all effect sizes as odds ratios (ORs) per copy of
the minor allele; an OR >1 indicates a higher mRS score
(worse outcome) per copy of the minor allele and an OR
<1 indicates a lower mRS score.
Investigationof expressionquantitative trait loci
We explored associations of the markers with p values <1 ×
10−5 and proxy SNPs (r2 > 0.8 in 1000 Genomes Phase 1
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European population) with expression quantitative trait loci
(eQTLs) in publicly available datasets encompassing numer-
ous tissues: Genotype-Tissue Expression (GTEx) V6,13
GRASP2,14,15 Human Genetic Variation Database (HGVD),16
and BIOS.17 For eQTLs, p < 10−4 was considered significant.
Gene-based analysis
Gene-based tests were performed for each meta-analysis
using VEGAS2 with linkage disequilibrium structure based
on the European population.18 All SNPs within ±10 kbp from
the untranslated regions 39 and 59 of each gene were in-
cluded, to account for potential regulatory variants.18 The
number of genes included was approximately 23,000, which
corresponds to a Bonferroni-corrected significance threshold
of p < 2.2 × 10−6.
Data availability
The datasets generated and analyzed during the current study
are available on reasonable request.
Results
Characteristics such as age, sex, and stroke severity, as well as the
numbers of included cases for each mRS score and in each
outcome analysis, are displayed in table 1. The analyses of mRS
0–2 vs 3–6 and the ordinal analyses included 6,021 stroke cases,
whereas analyses of mRS 0–1 vs 2–6 included 4,363 cases.
One common variant on chromosome 18q11.2 (rs1842681,
minor allele frequency: 0.23) was associated at genome-wide
Figure 1 Manhattan and quantile-quantile plots of analysis for associations with dichotomized mRS at 3 months
Outcome was measured as mRS 0–2 vs 3–6 at 3 months after ischemic stroke onset. Dotted lines show genome-wide significance (black, p <5 × 10−8) and
suggestive association level (green, p < 10−5). Results are adjusted for age, sex, principal components, and baseline NIH Stroke Scale score. mRS = modified
Rankin Scale.
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significance with outcome defined as mRS 0–2 vs 3–6 (OR
for minor allele [A]: 1.40, p = 5.3 × 10−9) (table 2, figures 1,
3, and 4). The effect was similar with and without adjustment
for stroke severity (table 2), and the association was ob-
served in the same direction, but with a somewhat lower
effect size, for ordinal mRS (OR: 1.17, p = 1.5 × 10−4) and
mRS 0–1 vs 2–6 (OR: 1.12, p = 7.4 × 10−2). In line with this,
the distribution of the minor allele count for rs1842681 over
mRS categories shows a threshold between mRS 2 and 3
(data available from Dryad, figure e-5, doi.org/10.5061/
dryad.s38kf65). The variant is located in an intron of the
gene LOC105372028 (long noncoding RNA synonymous
with RP11-449D8.5 [Genome Reference Consortium Hu-
man Build 38/hg38]) and is in a putative binding site of
several regulatory proteins (HaploReg, March 21, 2018). This
variant has no eQTL reported in GTEx (June 1, 2018).
However, in HGVD, it has a trans-eQTL for KLRAQ1 (also
known as PPP1R21, pHGVD = 1.67 ×10
−7). PPP1R21 is
expressed in the brain (GTEx, June 1, 2018).
No other SNP was significantly associated with mRS 0–2 vs
3–6, or with ordinal scale mRS (figures 1 and 2). The results
for the lead SNPs of the top 10 independent loci for each
outcome are displayed in data available fromDryad (tables e-5
and e-6, doi.org/10.5061/dryad.s38kf65). The results from
analyses without severity adjustment are displayed in data
available from Dryad (tables e-7 and e-8 and figures e-1, e-2,
e-6, and e-7). There were no signs of heterogeneity for the
effects of the reported SNPs. All I2 values were <0.35 and all p
for heterogeneity >0.08, except for one SNP (rs58448576) in
the analysis of mRS 0–1 vs 2–6, which had an I2 of 0.48 and a p
value of 0.03 (without adjustment for multiple testing). In the
gene-based analyses, no gene reached the predefined thresh-
old for significance (data available from Dryad, table e-9).
Figure 2Manhattan and quantile-quantile plots of analysis for associations with ordinal mRS at 3 months
Outcomewasmeasured as ordinalmRS at 3months after ischemic stroke onset. Dotted lines show genome-wide significance (black, p <5 × 10−8) and suggestive
association level (green, p < 10−5). Results are adjusted for age, sex, principal components, and baseline NIH Stroke Scale score. mRS = modified Rankin Scale.
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The analysis of mRS 0–1 vs 2–6 yielded no significant asso-
ciations. These results are presented in data available from
Dryad (tables e-12 and e-13 and figures e-3, e-4, and e-8, doi.
org/10.5061/dryad.s38kf65).
Suggestive associations with outcome
Thirty-three SNPs in 12 different loci (with at least 1 Mbp
distance) were suggestively (p < 10−5) associated with mRS
0–2 vs 3–6 (excluding the SNPs in the significant locus on
chromosome 18q11.2), and 75 SNPs in 17 different loci with
ordinal mRS (figures 1 and 2). Of these 29 independent loci,
the top SNPs of 16 loci have either significant eQTLs for and/
or are located within or near (<100 kbp) genes that are
expressed in the brain (GTEx, June 1, 2018). Five genes that
were not reported to be expressed in brain tissue were
expressed in arteries or lymphocytes (GTEx, June 1, 2018).
Among the suggestive associations, 3 are linked to genes with
experimental evidence of influence on outcome from animal
models of stroke and are discussed below.19–21 First,
rs2236406, an intron variant in the PTCH1 gene, was identified
in the mRS 0–2 vs 3–6 analysis (table 2, figures 3 and 4). The
gene-based analysis also showed a suggestive association for
PTCH1 with mRS 0–2 vs 3–6 (p = 6.8 × 10−5). Rs2236406 is
an eQTL for long noncoding RNA RP11-435O5.5 (pGTEx =
5.7 × 10−7), which overlaps the PTCH1 gene. Second, in the
ordinal analysis, a suggestive association with mRS was found
for rs13299556 (table 2, figures 3 and 4). Associations at low p
values were also found for this variant with dichotomous mRS,
althoughnot reaching the level for suggestive association (table 2).
rs13299556 is an intron variant in the PLAA gene. There was
no strong association for PLAA in the gene-based analysis
(ordinal mRS; p = 0.072). However, this variant, and variants in
high linkage disequilibrium with it (figure 4), are reported as
eQTLs for the nearby genes TEK and LRRC19 (pGTEx = 1.6 ×
10−6 for both). The p values from the gene-based analysis for
Table 1 Characteristics of the study population and
numbers of included patients for eachmRS score
and for each outcome (mRS 0–2 vs 3–6, 0–1 vs
2–6, and the full ordinal scale)
Total no. 6,165
Sex, M/F, n 3,497/2,668
Age, y, median (IQR) 70 (60–80)
NIHSS (0–10 d), median (IQR) 4 (2–8)
mRS score at 3 mo, n
0–2a 972
0 706
1 1,126
2 1,026
3 953
4 659
5 236
6 487
Outcomes, n
mRS 0–2 vs 3–6 3,741 vs 2,280b
Ordinal mRS 6,021b
mRS 0–1 vs 2–6 1,796 vs 2,567b
Abbreviations: IQR = interquartile range; mRS = modified Rankin Scale;
NIHSS = NIH Stroke Scale.
a Cases for which data from the Swedish quality register for stroke (Riks-
stroke) were used to assess mRS. This approach prevented differentiation
among mRS 0, 1, and 2.
b Numbers refer to the primary, fully adjusted model, including age,
sex, principal components, and baseline NIHSS score. Models without
adjustment for baseline NIHSS score included 3,830 vs 2,335 (mRS
0–2 vs 3–6), 6,165 (ordinal), and 1,832 vs 2,620 (mRS 0–1 vs 2–6)
participants.
Table 2 Comparison between analyses of mRS 0–2 vs 3–6 and ordinal scale mRS of selected genetic variants with either
a significant associationwith outcomeor a suggestive association and a link to a genewith experimental support
for influence on poststroke outcome
Marker MA MAF
mRS 0–2 vs 3–6 Ordinal mRS
Primary Not adjusted for NIHSS Primary Not adjusted for NIHSS
OR p Value OR p Value OR p Value OR p Value
rs1842681 A 0.23 1.40 5.27 × 10−9,a 1.30 1.46 × 10−7 1.17 1.53 × 10−4 1.19 2.98 × 10−5
rs2236406 C 0.36 1.27 3.43 × 10−6,a 1.21 1.98 × 10−5 1.13 9.11 × 10−4 1.11 3.96 × 10−3
rs13299556 C 0.27 1.25 6.25 × 10−5 1.22 2.93 × 10−5 1.20 5.69 × 10−6 1.21 7.59 × 10−7,a
rs78734480 C 0.03 0.57 4.79 × 10−4 0.66 2.34 × 10−3 0.58 1.03 × 10−6,a 0.62 5.00 × 10−6
Abbreviations: MA = minor allele; MAF = minor allele frequency; mRS = modified Rankin Scale; NIHSS = NIH Stroke Scale; OR = odds ratio.
ORs with effects above unity indicate a highermRS (worse outcome) per copy of theminor allele. Primarymodel includes age, sex, principal components, and
baseline NIHSS score.
a Indicates the outcome and model with the lowest p value for each marker.
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those genes were 0.0019 and 0.084, respectively. The variant
is also predicted to alter a putative regulatory motif sequence
(HaploReg, March 21, 2018). Third, a suggestive association
with ordinal mRS was found for an intron variant in NTN4
(rs78734480; table 2, figures 3 and 4). This variant was also
associated with dichotomous mRS at a low p value, although
not below the cutoff for suggestive association (table 2).
Analysis of lacunar and nonlacunar stroke
To evaluate whether any strong associations could be identified
specifically in patients with lacunar stroke (small vessel disease
strokes, n = 992), or in nonlacunar stroke (other etiologic sub-
types including cortical infarcts, n = 3,991), we analyzed those
groups separately. No genome-wide significant association was
detected (all p values >6 × 10−7). The top 5 findings differed
between these subgroups and are shown in data available from
Dryad (tables e-10 and e-11, doi.org/10.5061/dryad.s38kf65).
Discussion
This GWA study on functional outcome after ischemic stroke,
including more than 6,000 patients, identified one significant
locus and several suggestive variants related to genes with
a potential mechanism for influencing stroke recovery and
outcomes. Replication of these findings in independent
datasets as they become available is the essential next step.
The effect sizes of these genetic variants were generally small,
and further studies should include even larger samples to
identify additional variants associated with stroke outcome
and to enable subgroup analyses.
The genome-wide significant SNP (rs1842681) for mRS 0–2
vs 3–6 is an intronic variant in the gene LOC105372028 (long
noncoding RNA), the function of which remains to be estab-
lished. However, expression analyses show that the gene
Figure 3 Forest plots for functional outcome at 3 months by study cohort
The plots show ORs and 95% confidence intervals for minor allele of (A) rs1842681 (mRS 0–2 vs 3–6), (B) rs2236406 (mRS 0–2 vs 3–6), (C) rs13299556 (ordinal
mRS), and (D) rs78734480 (ordinal mRS). ORs with effects above unity indicate a higher mRS score (worse outcome) per copy of the minor allele. Results are
adjusted for age, sex, principal components, and baseline NIH Stroke Scale score. For cohort abbreviations, see data available fromDryad (table e-1, doi.org/
10.5061/dryad.s38kf65). mRS = modified Rankin Scale; OR = odds ratio.
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expression of LOC105372028 is highest in brain tissue (Na-
tional Center for Biotechnology Information, ncbi.nlm.nih.
gov/gene/?term=LOC105372028) and rs1842681 is located
in a putative regulatory element binding site (HaploReg,March
21, 2018). Furthermore, rs1842681 is a trans-eQTL for
KLRAQ1, also known as PPP1R21, which encodes a regulatory
subunit of protein phosphatase 1 (PP1). PP1 is a ubiquitous
phosphatase implicated in many brain functions including
learning andmemory formation.22,23 PP1 is also a key regulator
of Ca2+/calmodulin (CaM)-dependent protein kinase II
(CaMKII) signaling, which is crucial for Ca2+-mediated neu-
ronal plasticity in the brain.24 Thus, although speculative,
rs1842681 may modulate expression of PPP1R21, which in
turn could affect brain plasticity and thereby outcome post
stroke, a hypothesis that requires validation through functional
experiments. The association for rs1842681 with outcome was
observed after adjusting for baseline NIHSS score, suggesting
a mechanism that is independent of initial stroke severity.
However, additional data from further studies are clearly
needed to corroborate this finding and clarify the potential role
of this locus for functional outcome after stroke.
Twenty-nine independent loci were associated with ischemic
stroke outcome at the predefined suggestive association level.
Three of these loci are linked to genes with experimental
evidence of influence on outcome from animal models of
stroke.19–21 First, the intronic variant in PLAA (rs13299556)
was both one of the top findings in the ordinal analysis and
associated with the dichotomized outcome at a low p value. It
is located in a putative transcription factor binding site and is
reported to be an eQTL for the expression of both LRRC19
and TEK. LRRC19 encodes a protein with a potential role in
regulating neurite outgrowth,25 and might thus influence
stroke recovery. TEK encodes a tyrosine kinase pre-
dominantly expressed in endothelial cells (ECs). Focal
upregulation of TEK has been demonstrated in capillaries at
the border of infarcted myocardium, and expression is in-
duced by hypoxia and proinflammatory cytokines in human
Figure 4 Regional association plots for outcome at 3 months after ischemic stroke onset
(A) Significant locus (rs1842681) showing association with mRS 0–2 vs 3–6, (B) rs2236406 (intron variant in the PTCH1 gene) showing suggestive association
withmRS 0–2 vs 3–6, (C) rs13299556 (intron variant in the PLAA genewith eQTL for TEK, pGTEx = 1.6 × 10
−6) showing suggestive associationwith ordinalmRS, and
(D) rs78734480 (intron variant in the NTN4 gene) showing suggestive association with ordinal mRS. Results are adjusted for age, sex, principal components,
and baseline NIH Stroke Scale score. LOC105372028 (indicated in red, panel A) has been overlaid from the Genome Reference Consortium Human Build
(GRCh) 38/hg38, as it was missing from GRCh37/hg19. The rs1842681 variant is intronic of the LOC105372028 gene (chromosome 18: 24725781–24766645).
Position for rs1842681 inGRCh38/hg38, 18:24761199. eQTL = expression quantitative trait locus; GTEx =Genotype-Tissue Expression;mRS =modified Rankin
Scale; SNP = single-nucleotide polymorphism.
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ECs in vitro.26 TEK is activated by angiopoietin-1 and this
promotes migration, sprouting, and survival of ECs.27,28 Of
note, results from a rodent ischemic stroke model suggest that
upregulation of angiopoietin-1 and TEK improves stroke
outcome,19 and one clinical study reported an association
between high plasma levels of angiopoietin-1 and poor out-
come as assessed by mRS at 3 months after ischemic stroke.29
Angiopoietin-2 is the antagonist of angiopoietin-1.30
Angiopoietin-2 gain-of-function mice have enhanced blood-
brain barrier permeability and increased brain infarct sizes
upon permanent middle cerebral occlusion compared to wild-
type mice, and both phenotypes were rescued by activation of
TEK signaling.31 The same study reported increased circu-
lating serum concentrations of angiopoietin-2 in patients with
acute ischemic stroke compared to controls.31 Finally, in an
ischemic stroke model, mice with type 2 diabetes mellitus
showed increased angiopoietin-2 but decreased angiopoietin-
1/TEK protein expression compared to wild-type mice, sug-
gesting that the TEK signaling may be involved in diabetes-
induced vascular damage post stroke.32
Second, an intronic variant in the PTCH1 gene showed sug-
gestive association with mRS 0–2 vs 3–6. PTCH1 is involved
in sonic hedgehog signaling, a pathway that for instance
reduces oxidative stress on neurons and regulates ischemia-
induced neuronal progenitor proliferation.33,34 In rats with
experimentally induced middle cerebral artery occlusion, in-
hibition of the sonic hedgehog signaling caused increased
infarct size, and PTCH1 was downregulated when sonic
hedgehog signaling was inhibited.20,35 The association be-
tween PTCH1 and stroke outcome observed in the present
study may thus potentially be explained by an increased in-
farct size. However, the effect of this variant was somewhat
stronger when adjusting for baseline NIHSS score, which may
suggest a potential influence also on recovery processes.
Third, a variant inNTN4 showed suggestive association with
ordinal mRS and was also associated with dichotomous mRS
at a low p value. NTN4 encodes a member of the netrin
family of proteins expressed in brain tissue (ncbi.nlm.nih.
gov/gene/59277) and with functions in processes with bi-
ologically plausible roles in stroke recovery such as angio-
genesis, neurite growth, and migration.36,37 In a mouse
model, NTN4 was upregulated in blood vessels and astro-
cytes in the ischemic core after stroke, and intra-
cerebroventricular administration of NTN4 led to
improvements both in angiogenesis and in poststroke out-
come, possibly through increased collateral blood flow
leading to improved survival of neurons partially affected by
ischemia.21 In another study, NTN4 contributed to thala-
mocortical axon branching in rodents and the expression was
altered by neuronal activity in the cortex, implying that
NTN4 might act as a positive regulator for thalamocortical
axon branching through activity-dependent expression.38
Although highly speculative, this gene could thus have a role
in the plastic process of axonal outgrowth and restoration of
synaptic architecture post stroke.
Several additional variants with suggestive association to
outcome in this study are linked to genes that may potentially
be mechanistically involved in processes affecting stroke
outcomes. For instance, RUNX1 encodes a runt-related
proangiogenic transcription factor with high expression in
arteries (GTEx, June 1, 2018) that is upregulated after
stroke.39 In mice, expression of RUNX1 is induced in putative
neural stem or progenitor cells after brain injury and sug-
gested to promote neuronal differentiation.40 TNR encodes
a protein that is involved in neuronal plasticity and is highly
and exclusively expressed in the brain.41,42 Examples of genes
with a possible stroke subtype-specific significance among
suggestive findings are MTHFS, which is involved in folate
and homocysteine metabolism, pathways with potential in-
fluence on cerebral small vessel disease,43 and SCML4, in
which the variant rs74514008 was suggestively associated with
ordinal mRS in the present study. SCML4 has shown asso-
ciation with coronary artery disease in a recent GWA study,
and subsequent functional characterization suggested a role in
atherosclerosis.44
To further explore the SNPs associated with outcomes in
different subgroups, such as certain stroke subtypes, patients
with diabetes, or those receiving recanalization therapies
would be of great interest. Mechanisms of neuron injury and
recovery probably have similarities regardless of the etiology,
but mechanism of recovery after cortical and subcortical
stroke may be different. Therefore, we analyzed mRS 0–2 vs
3–6 in patients with lacunar and nonlacunar stroke separately.
The top 5 independent loci differed between the 2 groups, but
no genome-wide significant association was detected. Given
the small sample sizes, especially for lacunar stroke, these
analyses are clearly exploratory. Thus, in further studies with
a higher number of patients, an important aim will be to
further explore the genetic associations in specific subgroups.
The strengths of the present study include a relatively large
sample size, well defined endpoints, extensive genetic data, and
that analyses were adjusted for NIHSS score to assess the
influence on outcome independent of baseline stroke severity.
We performed dichotomous outcome analyses to identify ge-
netic variants associated with being dependent or independent
in activities of daily living, which reflects a clinically important
difference in functional outcome. We also performed ordinal
analysis, which aims to identify variants that have a similar effect
across different degrees of functional outcome. To detect such
variants, the ordinal model provides greater power.8 Another
strength of the ordinal approach is the ability to compensate for
any differences in mRS assessment between studies.
There are also several limitations that should be considered.
Although this study included more than 6,000 patients with
ischemic stroke, only one significant locus was identified, and
thus, the findings do not explain the assumed genetic variation
for ischemic stroke outcomes. This implies that the effect sizes
of individual SNPs on outcome of ischemic stroke are small
and that our sample size might be insufficient even to detect
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common genetic variants. Another important limitation is the
explorative nature of the results, which clearly require future
replication in independent cohorts as they become available.
The use of the mRS as the primary outcome metrics is a clear
limitation in that it is a crude measurement of outcome, es-
pecially when dichotomized. However, the mRS represents
a well-established, formalized, and easily available measure of
poststroke functional outcome, and the dichotomizations
represent differences of great importance clinically and for the
patient. ThemRS scores were assessed at different time points
ranging from 60 to 190 days, potentially diluting any detect-
able associations, as functional outcome status may vary over
time. However, the majority of included studies assessed mRS
at 3 months ± 2 weeks after stroke onset. We did not have
information on premorbid mRS and this would have provided
a valuable means to calculate the change in functional ability.
Moreover, stroke severity was scored at different time points.
However, in a majority of cases, NIHSS was scored early and
in only 160 individuals later than day 3 after admission. As
previously described,8 we lack data on some important factors
that influence outcomes such as acute therapies and re-
habilitation, which is why these factors could not be accounted
for in the analyses. However, data from the cohorts with
available data on treatment with tissue plasminogen activator
(about half of the cohorts) show that this treatment was given
to 14% of the patients. We can also not exclude the possibility
of selection bias since participation in the study required in-
dividual informed consent, and data entry also requested
availability of functional status follow-up data. In line with this,
our study sample mainly reflects milder strokes (median
NIHSS score of 4, table 1), which may hamper the detection of
factors influencing a greater dynamic range of recovery. Lastly,
because our study population was of European ancestry, the
results are not necessarily generalizable to other stroke pop-
ulations. Further studies should ideally include a series of
prespecified collection time points, specific clinical variables of
importance for stroke outcome, and a battery of outcome
metrics that assess several domains of recovery includingmotor
impairment, aphasia, neglect, and cognitive impairment.
In this first large international GWA study on functional outcome
after overall ischemic stroke, we report one significant variant and
several variants with suggestive association to outcome at 3
months after stroke onset with plausible links to poststroke re-
covery. Future studies on common variants should include larger
sample sizes, enabling subgroup analyses, as well as replication of
the present results and elaboration of potential mechanisms.
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